2. BBE. Data from series of 5 or more patients.
Study ID / Name | Treatment | N | n(%)Asymptomatic 6m | n(%)Asymptomatic 1m | n(%)Ventilated 1m | n(%)Dead 6m | n(%)Fluct / relapse | ? Adverse event |
Odaka 2003 | PE | 14 | 8 (57%) | ‐ | 2 (14%) | 1 (7%) | 1 (7%) | 1 cardiac arrest |
Steroids | 13 | 11 (85%) | ‐ | 0 | 0 | 0 | 0 | |
IVIg | 2 | 2 (100%) | ‐ | 0 | 0 | 0 | 0 | |
PE + steroids | 16 | 6 (38%) | ‐ | 4 (25%) | 0 | 0 | 0 | |
IVIg + steroids | 5 | 3 (60%) | ‐ | 0 | 0 | 0 | 0 | |
PE + IVIg | 2 | 0 | ‐ | 2 (100%) | 0 | 0 | 0 | |
PE + IVIg + steroids | 3 | 1 (33%) | ‐ | 1 (33%) | 1 (33%) | 0 | 1 respiratory obstruction | |
Natural history | 7 | 1 (14%) | ‐ | 1 (14%) | 1 (14%) | 0 | 1 meningitis | |
Yaqub 1989 | Natural history | 6 | 6 (100%) | 1 (17%) | 1 (17%) | 0 | 0 | 0 |
Kuntzer 1987 | Steroids (1), acyclovir (1) | 2 | 2 (100%) | 0 | 0 | 0 | ‐ | ‐ |
Natural history | 5 | 5 (100%) | 1 (20%) | 1 (20%) | 0 | ‐ | 1 pneumonia | |
Al‐Din 1982 | ACTH or prednisolone | 3 | 2 (67%) | 1 (33%) | 0 | 0 | 0 | 0 |
Natural history | 10 | 7 (70%) | 0 | 1 (10%) | 1 (10%) | 0 | 1 chest infection + pulmonary embolism |